SUNHO (CHINA) BIOPHARMACEUTICAL CO.,LTD

SunHo is a clinical-stage biopharmaceutical company with a global vision dedicated to the discovery, development, manufacturing and commercialization of innovative antibody products and fusion proteins in the fields of cancer immunotherapy, autoimmune diseases, and neurodegenerative disorders. We have developed proprietary and patented Armed ImmunoCytokine Platform (AIC™), Armed Innate Effector Multispecific Platform (AIM™), and ADCC Enhanced Antibody Platform (AEA™). With profound understanding of immunology and tumor microenvironment, we strive to identify and meet the most critical clinical needs, as evidenced by our pipeline of over 20 truly innovative and differentiated products, of which 4 are undergoing clinical trials, 4 in IND application and 6 are at the pre-clinical stage.

Talented minds hold the key to our success. Every member of our leadership team has over 10 years of successful discovery, development and commercialization experiences in renowned biopharmaceuticals. Together, they lead a team with exceptional expertise in R&D, process development, CMC, regulatory affairs, manufacture, and clinical trials.

We are also proud of our GMP-compliant manufacturing capability that enables process development, clinical manufacture, and commercial manufacture. Our quality management system lives up to the expectations of U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China's National Medicinal Products Administration (NMPA).

Our facility offers manufacture solutions from drug substance (DS) to drug product (DP) production. 1× 1000 L and 3× 200 L GMP bioreactor lines are available for DS production, and another 2x5000 L lines are coming soon. 1× liquid filling line and 1× lyophilization line also cater to the need of aseptic processing of biologics (liquid and lyophilized preparations) for clinical trials and commercialization.

With proprietary and patented R&D platforms, highly experienced and motivated talents, and state-of-art GMP manufacturing capabilities, we focus on Antibody and Cytokine to build the next leading global biopharma of immunotherapy, and to bring perceivable benefits and affordable medicine to patients worldwide, by innovation and collaboration.